Literature DB >> 17376680

Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives.

Tatsuya Horio1, Tomohiro Hamasaki, Toshihiko Inoue, Tatsushi Wakayama, Shinsaku Itou, Haruna Naito, Tetsuo Asaki, Hiroki Hayase, Tomoko Niwa.   

Abstract

To investigate why 3-substituted benzamide derivatives show dual inhibition of Abl and Lyn protein tyrosine kinases, we determined their inhibitory activities against Abl and Lyn, carried out molecular modeling, and conducted a structure-activity relationship study with the aid of a newly determined X-ray structure of the Abl/Lyn dual inhibitor INNO-406 (formerly known as NS-187) bound to human Abl. We found that this series of compounds interacted with both kinases in very similar ways, so that they can inhibit both kinases effectively.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376680     DOI: 10.1016/j.bmcl.2007.03.002

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states.

Authors:  Irina Kufareva; Ruben Abagyan
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

2.  NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor.

Authors:  Tomoko Niwa; Tetsuo Asaki; Shinya Kimura
Journal:  Anal Chem Insights       Date:  2007-11-14

3.  An Open Library of Human Kinase Domain Constructs for Automated Bacterial Expression.

Authors:  Steven K Albanese; Daniel L Parton; Mehtap Işık; Lucelenie Rodríguez-Laureano; Sonya M Hanson; Julie M Behr; Scott Gradia; Chris Jeans; Nicholas M Levinson; Markus A Seeliger; John D Chodera
Journal:  Biochemistry       Date:  2018-07-26       Impact factor: 3.162

4.  Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.

Authors:  Jie Zhao; Haitian Quan; Yongping Xu; Xiangqian Kong; Lu Jin; Liguang Lou
Journal:  Cancer Sci       Date:  2014-01-04       Impact factor: 6.518

5.  A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.

Authors:  Uwe Rix; Jacques Colinge; Katharina Blatt; Manuela Gridling; Lily L Remsing Rix; Katja Parapatics; Sabine Cerny-Reiterer; Thomas R Burkard; Ulrich Jäger; Junia V Melo; Keiryn L Bennett; Peter Valent; Giulio Superti-Furga
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

6.  Bcr-Abl tyrosine kinase inhibitors- current status.

Authors:  Anum Mughal; Hafiz Muhammad Aslam; Aga Muhammad Hammad Khan; Shafaq Saleem; Ribak Umah; Maria Saleem
Journal:  Infect Agent Cancer       Date:  2013-06-20       Impact factor: 2.965

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.